Recommendation for Vaccinations in Patients with Crohn’s Disease and Ulcerative Colitis on Immunosuppressive and/or Biological Therapy
Authors:
J. Stehlík 1; K. Mareš 2; M. Lukáš 3; M. Bortlík 3; D. Ďuricová 3; Pracovní Skupina Pro Idiopatické Střevní Záněty Čgs
Authors‘ workplace:
Interní oddělení, Masarykova nemocnice, Ústí nad Labem
1; Interní oddělení Nemocnice na Homolce, Praha
2; ISCARE IVF a. s. a 1. LF UK v Praze
3
Published in:
Gastroent Hepatol 2010; 64(1): 40-48
Category:
IBD
Overview
Patients with Crohn’s disease and ulcerative colitis on immunosuppressive or biological therapy are exposed to a significantly higher risk of infectious complications. Therefore, these patients require systematic and complex precautions which are focused on the early detection and target treatment of these potentially serious complications. Vaccination at the time of diagnosis of inflammatory bowel disease or before initiating the biological and/or immunosuppressive therapy has become extraordinarily important. From the clinical point of view, the vaccinations against virus hepatitis B, human papilomavirus, varicella zoster infection and pneumococcal infection are the most important. The life vaccine application is allowed 3 months after biological or immunosuppressive therapy is terminated. Treatment with immunosuppressants and biological preparations is strongly recommended not to begin earlier than 3 weeks after life vaccine application. The present recommendations are based on the consensus of the Czech IBD Working Group and the ECCO Statement.
Klíčová slova:
Crohn’s disease – ulcerative colitis – inflammatory bowel diseases – vaccinations – biological therapy – immunosuppressive therapy
Sources
1. Rutgeerts P, Vermeire S, Van AG. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136(5): 1182–1197.
2. de Ridder L, Escher JC, Bouquet J et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39(1): 46–52.
3. Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6(11): 1212–1217.
4. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541–1549.
5. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn‘s disease: results of the CLASSIC II trial. Gut 2007; 56(9): 1232–1239.
6. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501–508.
7. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn‘s disease: results from a single-centre cohort. Gut 2009; 58(4): 492–500.
8. Rahier J, Ben-Horin S, Chowers Y et al. Europen evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn´s and Colitis 2009; 3: 47–91.
9. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098–1104.
10. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn‘s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4(5): 621–630.
11. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 1993; 42: 1–18.
12. Symmers WS. Opportunistic infections. The concept of „opportunistic infections“. Proc R Soc Med 1965; 58: 341-346.
13. Toruner M, Loftus EV jr., Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134(4): 929–936.
14. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31(2): 578–585.
15. Ainley C, Cason J, Slavin BM et al. The influence of zinc status and malnutrition on immunological function in Crohn‘s disease. Gastroenterology 1991; 100(6): 1616–1625.
16. Lu Y, Jacobson DL, Ashworth LA et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104(2): 444–453.
17. Brezinschek HP, Hofstaetter T, Leeb BF et al. Immunization of patients with rheumatoid arthritis with antitumor necro-sis factor alpha therapy and methotre-xate. Curr Opin Rheumatol 2008; 20(3): 295–299.
18. Mamula P, Markowitz JE, Piccoli DA et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5(7): 851–856.
19. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360(25): 2605–2615.
20. Baker MG, Wilson N, Huang QS et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill 2009; 14.
21. Vaillant L, La RG, Tarantola A et al. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14.
22. Rahier JF, Yazdanpanah Y, Viget N et al. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31(1): 5–10.
23. Medicines Q&A: Use of Oseltamivir in Patients Taking Methotrexate. 2009.
24. Beasley RP, Hwang LY, Lin CC et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146(2): 198–204.
25. Coursaget P, Yvonnet B, Chotard J et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22(1): 1–5.
26. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31(2): 488–495.
27. Rehermann B, Ferrari C, Pasquinelli C et al. The hepatitis B virus persists for decades after patients‘ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2(10): 1104–1108.
28. Yotsuyanagi H, Yasuda K, Iino S et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27(5): 1377–1382.
29. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45(2): 507–539.
30. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37(6): 1320–1328.
31. Šperl J, Špičák J. Problematika virových hepatitid v průběhu léčby preparáty s antiTNFa aktivitou. Biol Lecbva 2010; 2:69.
32. Tilg H, Vogelsang H, Ludwiczek O et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003; 52(12): 1728–1733.
33. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15(4): 130–133.
34. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38(3): 189–197.
35. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1–24.
36. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57(1): 7–28.
37. Saunders W. The Imunology of Pregnancy. Maternal-fetal Medicine: Principles and Practice. Philadelphia, PA: 1994.
38. Mahadevan U, Terdiman J, Church J et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2010; 132: A144.
39. Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4(10): 1255–1258.
40. Hill DR, Ericsson C, Pearson R et al. The practice of travel medicine: guidelines by the Infectious Disease Society of America. Clin Infect Dis 2006; 43: 1499–1539.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2010 Issue 1
Most read in this issue
- The Diagnosis and Treatment of Globus Pharyngeus
- Recommendation for Vaccinations in Patients with Crohn’s Disease and Ulcerative Colitis on Immunosuppressive and/or Biological Therapy
- Neuroendocrine Tumors of the Large Bowel
- Enteropathy-Associated Non-Hodgkin T-Lymphoma as a Complication of Late Diagnosis of Celiac Disease in a Geriatric Patient